Sarepta Therapeutics has entered a research partnership and option agreement with GenEdit to develop gene-editing therapies for neuromuscular diseases. The alliance will leverage the NanoGalaxy platform of GenEdit and Sarepta’s gene-editing technology to develop the […]
UCB has signed a definitive agreement to acquire rare diseases therapies developer Zogenix in a deal valued at about $1.9bn. Under the deal, the company will initiate a tender offer through its subsidiary Zinc Merger […]
Sanofi and Exscientia have entered a research partnership and licence agreement for the development of up to 15 new small-molecule medicines across oncology and immunology. The precision-engineered medicines will be developed using an end-to-end artificial […]
Bristol Myers Squibb (BMS) has signed a research partnership and licence agreement with Century Therapeutics for hematologic malignancies and solid tumour therapy development. Under the alliance, the companies will develop and market up to four […]
Gerresheimer has entered an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer’s innovative strength and engineering expertise for the development of a new pump to deliver a […]